<p>Stevens Capital Management LP 在第二季度購買了強生公司（NYSE:JNJ - 免費報告）的新股份，根據該公司最近向證券交易委員會提交的 13F 表格。該機構投資者購買了 12,443 股公司的股票，價值約為 1,901,000 美元。</p>
<p>獲取 <strong>強生</strong> 的提醒：</p>
<ul>
<li>為什麼 GRAIL 股票可能是生物科技的下一個重大突破</li>
</ul>
<p>其他對沖基金和機構投資者最近也調整了對該公司的持股。GFG Capital LLC 在第二季度購買了價值約 35,000 美元的強生新股份。Stone House Investment Management LLC 在第一季度購買了價值約 47,000 美元的強生新股份。1248 Management LLC 在第一季度購買了價值 48,000 美元的強生新股份。Harvest Fund Management Co. Ltd 在第一季度購買了價值約 52,000 美元的強生新股份。最後，Pandora Wealth Inc. 在第一季度購買了價值 65,000 美元的強生新股份。目前 69.55% 的股票由對沖基金和其他機構投資者持有。</p>
<h2>內部買賣</h2>
<p>在相關消息中，執行副總裁 Jennifer L. Taubert 於 9 月 4 日星期四出售了 56,471 股公司的股票。股票以平均價格 177.81 美元出售，總價值為 10,041,108.51 美元。出售完成後，該執行副總裁持有 178,013 股公司的股票，價值 31,652,491.53 美元。這代表其持股減少了 24.08%。該交易已在向證券交易委員會提交的文件中披露，文件可通過 SEC 網站獲取。目前公司內部人士持有 0.16% 的股票。</p>
<h2>華爾街分析師預測增長</h2>
<ul>
<li>3 只適合不安市場的聰明防禦性股票</li>
</ul>
<p>多家券商對 JNJ 發表了看法。Sanford C. Bernstein 將強生的目標價格從 172.00 美元上調至 193.00 美元，並在 10 月 6 日的研究報告中給予該公司 “市場表現” 評級。Johnson Rice 對強生的股票設定了 190.00 美元的目標價格，並在 10 月 22 日的報告中給予該股票 “持有” 評級。滙豐銀行將強生股票的目標價格從 210.00 美元上調至 215.00 美元，並在 10 月 16 日的研究報告中給予該公司 “買入” 評級。瑞銀集團將強生的目標價格從 190.00 美元上調至 214.00 美元，並在 10 月 14 日的研究報告中給予該公司 “買入” 評級。最後，Argus 在 10 月 15 日的報告中對強生股票設定了 210.00 美元的目標價格。四位股票研究分析師給予該股票 “強烈買入” 評級，十三位給予 “買入” 評級，九位給予 “持有” 評級。根據 MarketBeat，強生的共識評級為 “適度買入”，平均目標價格為 201.05 美元。</p>
<p><strong>查看我們對 JNJ 的最新分析</strong></p>
<h2>強生股票表現</h2>
<ul>
<li>持有評級，高回報？3 只可能超出預期的股票</li>
</ul>
<p>強生股票在週五開盤價為 203.88 美元。該公司的速動比率為 0.80，流動比率為 1.07，債務與股本比率為 0.50。該公司的市值為 4912.1 億美元，市盈率為 19.68，市盈增長比率為 2.19，貝塔值為 0.38。該公司的 50 日簡單移動平均為 188.25 美元，200 日簡單移動平均為 171.55 美元。強生的 52 周低點為 140.68 美元，52 周高點為 206.94 美元。</p>
<p>強生（NYSE:JNJ - 獲取免費報告）最近在 8 月 30 日星期三發佈了季度收益數據。該公司報告每股收益為 2.26 美元。該季度的營業收入為 240.2 億美元。強生的股本回報率為 32.73%，淨利潤率為 27.26%。股票分析師預測強生在當前年度的每股收益將達到 10.58 美元。</p>
<h2>強生股息公告</h2>
<p>該公司最近還宣佈了一項季度股息，將於 12 月 9 日星期二支付。11 月 25 日星期二的股東將獲得每股 1.30 美元的股息。除息日期為 11 月 25 日星期二。這代表年化股息為 5.20 美元，股息收益率為 2.6%。強生的派息比率為 50.19%。</p>
<h2>強生公司簡介</h2>
<p>（免費報告）</p>
<p>強生是一家控股公司，專注於醫療保健領域的產品研究、開發、製造和銷售。它通過創新藥物和醫療技術兩個部門運營。創新藥物部門專注於免疫學、傳染病、神經科學、腫瘤學、心血管和代謝以及肺動脈高壓。</p>
<h2>精選故事</h2>
<ul>
<li>五隻我們更看好的股票超過強生</li>
<li>便士股票適合你的投資組合嗎？</li>
<li>收入投資者注意：這隻 REIT 正在打折</li>
<li>最大股票虧損者 - 今天最大百分比下跌者</li>
<li>Rocket Lab 剛經歷了第一次真正的崩潰——反彈可能更大</li>
<li>標普 500 股票告訴投資者市場的什麼？</li>
<li>MarketBeat 週迴顧 – 11/17 - 11/21</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUpOSg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUpOSg"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在強生嗎？</h2>
<p>在考慮強生之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其向客户推薦的股票。MarketBeat 已經識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而強生並不在名單上。</p>
<p>雖然強生目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

強生

<p>Stevens Capital Management LP 在第二季度收購了價值 1,901,000 美元的強生（NYSE:JNJ）12,443 股，具體信息見其最新的 SEC 文件。其他機構投資者也調整了他們的持股。強生的股票在週五開盤價為 203.88 美元，市值為 4,912.1 億美元。分析師對該股票給予了 “適度買入” 的共識評級，平均目標價格為 201.05 美元</p>

<p>Stevens Capital Management LP bought a new stake in Johnson &amp; Johnson (NYSE:JNJ - Free Report) during the second quarter, according to the company in its most recent Form 13F filing with the Securities &amp; Exchange Commission. The institutional investor bought 12,443 shares of the company's stock, valued at approximately $1,901,000.</p>
<div class="lb-trans"><p>Stevens Capital Management LP 在第二季度購買了強生公司（NYSE:JNJ - 免費報告）的新股份，根據該公司最近向證券交易委員會提交的 13F 表格。該機構投資者購買了 12,443 股公司的股票，價值約為 1,901,000 美元。</p>
</div><p>Get <strong>Johnson &amp; Johnson</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>強生</strong> 的提醒：</p>
</div><ul>
<li>Why GRAIL Stock Could Be Biotech’s Next Big Breakout</li>
</ul>
<div class="lb-trans"><ul>
<li>為什麼 GRAIL 股票可能是生物科技的下一個重大突破</li>
</ul>
</div><p>Other hedge funds and other institutional investors have also recently modified their holdings of the company. GFG Capital LLC bought a new position in Johnson &amp; Johnson in the 2nd quarter worth approximately $35,000. Stone House Investment Management LLC purchased a new position in shares of Johnson &amp; Johnson in the 1st quarter worth approximately $47,000. 1248 Management LLC purchased a new stake in shares of Johnson &amp; Johnson in the first quarter valued at $48,000. Harvest Fund Management Co. Ltd bought a new stake in Johnson &amp; Johnson in the first quarter worth about $52,000. Finally, Pandora Wealth Inc. purchased a new position in Johnson &amp; Johnson during the 1st quarter valued at $65,000. 69.55% of the stock is currently owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>其他對沖基金和機構投資者最近也調整了對該公司的持股。GFG Capital LLC 在第二季度購買了價值約 35,000 美元的強生新股份。Stone House Investment Management LLC 在第一季度購買了價值約 47,000 美元的強生新股份。1248 Management LLC 在第一季度購買了價值 48,000 美元的強生新股份。Harvest Fund Management Co. Ltd 在第一季度購買了價值約 52,000 美元的強生新股份。最後，Pandora Wealth Inc. 在第一季度購買了價值 65,000 美元的強生新股份。目前 69.55% 的股票由對沖基金和其他機構投資者持有。</p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>內部買賣</h2>
</div><p>In related news, EVP Jennifer L. Taubert sold 56,471 shares of the company's stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the sale, the executive vice president owned 178,013 shares in the company, valued at $31,652,491.53. This represents a 24.08% decrease in their position. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available through the SEC website. 0.16% of the stock is currently owned by company insiders.</p>
<div class="lb-trans"><p>在相關消息中，執行副總裁 Jennifer L. Taubert 於 9 月 4 日星期四出售了 56,471 股公司的股票。股票以平均價格 177.81 美元出售，總價值為 10,041,108.51 美元。出售完成後，該執行副總裁持有 178,013 股公司的股票，價值 31,652,491.53 美元。這代表其持股減少了 24.08%。該交易已在向證券交易委員會提交的文件中披露，文件可通過 SEC 網站獲取。目前公司內部人士持有 0.16% 的股票。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>華爾街分析師預測增長</h2>
</div><ul>
<li>3 Smart Defensive Stocks for an Uneasy Market</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只適合不安市場的聰明防禦性股票</li>
</ul>
</div><p>A number of brokerages have weighed in on JNJ. Sanford C. Bernstein lifted their target price on Johnson &amp; Johnson from $172.00 to $193.00 and gave the company a &#34;market perform&#34; rating in a research report on Monday, October 6th. Johnson Rice set a $190.00 price target on shares of Johnson &amp; Johnson and gave the stock a &#34;hold&#34; rating in a report on Wednesday, October 22nd. HSBC increased their price objective on shares of Johnson &amp; Johnson from $210.00 to $215.00 and gave the company a &#34;buy&#34; rating in a research report on Thursday, October 16th. UBS Group boosted their price target on Johnson &amp; Johnson from $190.00 to $214.00 and gave the company a &#34;buy&#34; rating in a research note on Tuesday, October 14th. Finally, Argus set a $210.00 target price on shares of Johnson &amp; Johnson in a report on Wednesday, October 15th. Four equities research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and nine have given a Hold rating to the stock. According to MarketBeat, Johnson &amp; Johnson has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $201.05.</p>
<div class="lb-trans"><p>多家券商對 JNJ 發表了看法。Sanford C. Bernstein 將強生的目標價格從 172.00 美元上調至 193.00 美元，並在 10 月 6 日的研究報告中給予該公司 “市場表現” 評級。Johnson Rice 對強生的股票設定了 190.00 美元的目標價格，並在 10 月 22 日的報告中給予該股票 “持有” 評級。滙豐銀行將強生股票的目標價格從 210.00 美元上調至 215.00 美元，並在 10 月 16 日的研究報告中給予該公司 “買入” 評級。瑞銀集團將強生的目標價格從 190.00 美元上調至 214.00 美元，並在 10 月 14 日的研究報告中給予該公司 “買入” 評級。最後，Argus 在 10 月 15 日的報告中對強生股票設定了 210.00 美元的目標價格。四位股票研究分析師給予該股票 “強烈買入” 評級，十三位給予 “買入” 評級，九位給予 “持有” 評級。根據 MarketBeat，強生的共識評級為 “適度買入”，平均目標價格為 201.05 美元。</p>
</div><p><strong>Check Out Our Latest Analysis on JNJ</strong></p>
<div class="lb-trans"><p><strong>查看我們對 JNJ 的最新分析</strong></p>
</div><h2>Johnson &amp; Johnson Stock Performance</h2>
<div class="lb-trans"><h2>強生股票表現</h2>
</div><ul>
<li>Hold Ratings, High Rewards? 3 Stocks That Could Defy Expectations</li>
</ul>
<div class="lb-trans"><ul>
<li>持有評級，高回報？3 只可能超出預期的股票</li>
</ul>
</div><p>Shares of Johnson &amp; Johnson stock opened at $203.88 on Friday. The company has a quick ratio of 0.80, a current ratio of 1.07 and a debt-to-equity ratio of 0.50. The firm has a market cap of $491.21 billion, a PE ratio of 19.68, a price-to-earnings-growth ratio of 2.19 and a beta of 0.38. The business's fifty day simple moving average is $188.25 and its 200-day simple moving average is $171.55. Johnson &amp; Johnson has a 52 week low of $140.68 and a 52 week high of $206.94.</p>
<div class="lb-trans"><p>強生股票在週五開盤價為 203.88 美元。該公司的速動比率為 0.80，流動比率為 1.07，債務與股本比率為 0.50。該公司的市值為 4912.1 億美元，市盈率為 19.68，市盈增長比率為 2.19，貝塔值為 0.38。該公司的 50 日簡單移動平均為 188.25 美元，200 日簡單移動平均為 171.55 美元。強生的 52 周低點為 140.68 美元，52 周高點為 206.94 美元。</p>
</div><p>Johnson &amp; Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. The business had revenue of $24.02 billion during the quarter. Johnson &amp; Johnson had a return on equity of 32.73% and a net margin of 27.26%. Equities analysts forecast that Johnson &amp; Johnson will post 10.58 earnings per share for the current year.</p>
<div class="lb-trans"><p>強生（NYSE:JNJ - 獲取免費報告）最近在 8 月 30 日星期三發佈了季度收益數據。該公司報告每股收益為 2.26 美元。該季度的營業收入為 240.2 億美元。強生的股本回報率為 32.73%，淨利潤率為 27.26%。股票分析師預測強生在當前年度的每股收益將達到 10.58 美元。</p>
</div><h2>Johnson &amp; Johnson Dividend Announcement</h2>
<div class="lb-trans"><h2>強生股息公告</h2>
</div><p>The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 9th. Stockholders of record on Tuesday, November 25th will be given a dividend of $1.30 per share. The ex-dividend date is Tuesday, November 25th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.6%. Johnson &amp; Johnson's payout ratio is 50.19%.</p>
<div class="lb-trans"><p>該公司最近還宣佈了一項季度股息，將於 12 月 9 日星期二支付。11 月 25 日星期二的股東將獲得每股 1.30 美元的股息。除息日期為 11 月 25 日星期二。這代表年化股息為 5.20 美元，股息收益率為 2.6%。強生的派息比率為 50.19%。</p>
</div><h2>Johnson &amp; Johnson Profile</h2>
<div class="lb-trans"><h2>強生公司簡介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>Johnson &amp; Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.</p>
<div class="lb-trans"><p>強生是一家控股公司，專注於醫療保健領域的產品研究、開發、製造和銷售。它通過創新藥物和醫療技術兩個部門運營。創新藥物部門專注於免疫學、傳染病、神經科學、腫瘤學、心血管和代謝以及肺動脈高壓。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精選故事</h2>
</div><ul>
<li>Five stocks we like better than Johnson &amp; Johnson</li>
<li>Are Penny Stocks a Good Fit for Your Portfolio?</li>
<li>Attention Income Investors: This REIT Is on Sale</li>
<li>Biggest Stock Losers - Today’s Biggest Percentage Decliners</li>
<li>Rocket Lab Just Had Its First Real Crash—The Rebound Could Be Bigger</li>
<li>What Do S&amp;P 500 Stocks Tell Investors About the Market?</li>
<li>MarketBeat Week in Review – 11/17 - 11/21</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票超過強生</li>
<li>便士股票適合你的投資組合嗎？</li>
<li>收入投資者注意：這隻 REIT 正在打折</li>
<li>最大股票虧損者 - 今天最大百分比下跌者</li>
<li>Rocket Lab 剛經歷了第一次真正的崩潰——反彈可能更大</li>
<li>標普 500 股票告訴投資者市場的什麼？</li>
<li>MarketBeat 週迴顧 – 11/17 - 11/21</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUpOSg" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=JNJ"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Johnson &amp; Johnson Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在強生嗎？</h2>
</div><p>Before you consider Johnson &amp; Johnson, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮強生之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson &amp; Johnson wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其向客户推薦的股票。MarketBeat 已經識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而強生並不在名單上。</p>
</div><p>While Johnson &amp; Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然強生目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Stevens Capital Management LP 在強生公司 $JNJ 中建立了頭寸